TechNavio recognizes the following companies as the key players in the Future Prospects of Global Personalized Medicine Market: Abbott Laboratories Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., and Sanofi S.A.
Commenting on the report, an analyst from TechNavio’s team said: “Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011.”
According to the report, one of the key drivers in this market is the significant growth of the Targeted Biologics segment. This segment is one of the significant segments of personalized medicine and is expected to signify about 25 percent of the commercialized drugs during the forecast period.
Further, the report states that one of the major challenges is patients’ limited awareness about personalized medicines in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicines.
The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are Affymetrix Inc., Agendia B.V., Agilent Technologies Inc., Amgen Inc., Astellas Pharma Inc., Baxter International Inc., Bayer AG, BG Medicine Inc., Biocartis S.A., Biogen Idec Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., Celgene Corp., Daiichi Sankyo Co. Ltd., Danaher Corp., Eli Lilly and Co., Evotec AG, GE Healthcare Ltd., Genelex Corp., GlaxoSmithKline plc, Hologic Inc., Johnson & Johnson, Laboratory Corporation of America Holdings, Life Technologies Corp., Merck KGaA, Mitsubishi Tanabe Pharma Corp., Myriad Genetics Inc., PerkinElmer Inc., Quest Diagnostics Inc., Siemens Healthcare, Sigma-Aldrich Corp., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Transgenomic Inc.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit https://www.technavio.com/content/future-prospects-global-personalized-me…
TechNavio, the market research platform of Infiniti Research Ltd., publishes periodic market research reports on niche and emerging technologies. For more information on our market research, please visit https://www.technavio.com/healthcare-chemicals-food-retail
Follow us on Twitter @ Technavio
TechNavio Announces the Publication of its Research Report -Future Prospects of Global Personalized Medicine Market 2012-2016
